KRAS WT ALLELE

Clinical trials for KRAS WT ALLELE explained in plain language.

Never miss a new study

Get alerted when new KRAS WT ALLELE trials appear

Sign up with your email to follow new studies for KRAS WT ALLELE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Triple-Threat cancer therapy enters first human safety tests

Disease control Ongoing

This early-stage trial is testing the safety and best dose of a three-drug combination (vemurafenib, cetuximab, and irinotecan) for patients with advanced solid tumors that have spread and carry a specific BRAF gene mutation. The goal is to see if combining these drugs—two that b…

Matched conditions: KRAS WT ALLELE

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

KRAS WT ALLELE

Get alerted when new KRAS WT ALLELE trials appear

New Triple-Threat cancer therapy enters first human safety tests